BioCentury
ARTICLE | Clinical News

Apricitabine: Phase III ongoing

June 8, 2009 7:00 AM UTC

An independent DSMB recommended continuation of Avexa's international Phase III trial evaluating apricitabine at the 800 mg dose based on 16-week data from 3 treatment arms comparing 800 or 1,200 mg o...